To investigate the prognosis of primary melanoma, we studied a Finnish population of 298 primary melanoma patients, the majority with stage I or II tumours. The median clinical follow-up (4.8 years) was acquired from the patients' records, and the overall survival thereafter was collected from patient registries. The median follow-up for overall survival was 9.5 years.
INTRODUCTION
Local melanoma is usually curable by adequate surgery; patients with a thin primary cutaneous melanoma (depth ≤ 0.75 mm) have a 5-year survival rate of approximately 95-99 % (1, 2). The deeper the tumour, the worse is the prognosis. Patients with a melanoma of 0.76-1.49 mm Breslow depth have a 5-year survival rate of 80-95 %, whereas at a Breslow depth of 1.50-4.00 mm the corresponding rate is 60-75 % and at > 4.00 mm less than 50 %. If the lymph nodes are involved, the overall 5-year survival rate is only 30-40 %. More advanced metastasized disease is usually incurable and the median survival is 6 months (1, 2, 3).
Surgical removal of a primary tumour is the established treatment of choice. From 1907 (4) until 1970 (5) wide excision with 5-cm margins including regional lymph node dissection was recommended for all melanomas. In 1970 Breslow introduced the concept that prognosis was correlated with tumour thickness and challenged the dogma of wide excision (5). In 1977, Breslow and Macht described a series of 35 patients with thin melanoma treated with narrower margins (6). Today, the recommendations for the surgical margins of primary melanoma are based on prospective randomized trials (7, 8) . The necessity of lymph node dissection as a prophylactic procedure is still a controversial issue (9, 10, 11) . The new concept of the sentinel lymph node, defined by Morton as the first node in the lymphatic basin that drains the primary melanoma, has been documented to contain the first site of metastasized disease. This technology can be used to stage nodally the melanoma patient, and to identify the subgroup of patients (stage III) with an increased relapse rate. An advance in the treatment of metastasized melanoma patients is now eagerly awaited (12, 13, 14) .
Here we wanted to investigate how 298 primary melanoma patients survived and to compare the outcome with previous Finnish studies. We identified the most important clinical and histopathological prognostic factors in this patient group.
PATIENTS AND METHODS

PATIENTS
The subjects in our study consisted of 306 melanoma patients treated at the Department of Plastic Surgery, Helsinki University Hospital, and registered as primary malignant melanoma patients in 1988-1991. Eight of the thempatients were excluded because re-examination of their tumours did not confirm since the diagnosisturned out to be something other than of melanoma. The disease history concerning the status of a pre-existing naevus and the social status of the patient were collected from the patients' records.
DEFINITION OF THE TUMOUR PATHOLOGY
The primary melanoma samples were re-examined by an expert pathologist to verify the melanoma diagnosis. The Breslow and Clark classifications were also re-confirmed. Thereafter the patients were divided into in-situ or stage I-IV groups according to the American Joint Committee on Cancer (AJCC) staging system (15) . If the pathologist could see ulceration on the surface of the tumour, the specimen was coded ulceration positive. At the time of our study the new technique of detecting nodal micrometastasis by examining sentinel node was not yet used. Because of the lack of information about possible nodal micrometastasis we could not use the new proposed TNM classification in our study (16) .
FOLLOW-UP
The patients operated on were seen by a doctor every 3 months during the first 2 years, and thereafter every 6 months up to 5 years. Special attention was focused on the surgically treated area and the regional lymph nodes and on any suspicious skin lesions elsewhere in the body. Inspection and palpation were the most practical methods and if anything resembling a melanoma recurrence or metastasis was found, a fine needle sample of the questionable lesion was taken. If a patient would need surgery later, this was documented as was the possible need for consultations with and treatments by oncologists. Radiological examinations were conducted as required on the basis of clinical status. The final status was determined after the prospective clinical follow-up describing whether the patient was disease-free, had developed recurrences or metastasis or had died of melanoma. Thereafter, additional information was gathered from patient registries as to whether the patient had died of melanoma or some other cause or was still alive.
STATISTICS
The data were analysed by the StatView TM statistical program. The distribution of the measured parameters was characterized by standard descriptive methods. The relationship between observations was evaluated by contingency tables with χ 2 tests. In univariate analysis cumulative survival curves for both disease-free survival and overall survival were calculated according to the method of Kaplan and Meier and differences in survival were tested with the Mantel-Cox (log-rank) test. The starting point for both disease-free and overall survival was defined as the date of diagnosis. The end-point for disease-free survival was defined as the last day before metastases were discovered according to patient documents and for overall survival the day when the patient had died of melanoma according to patient registries. The multiple regression analysis was used to show the diminishing of surgical margins in years 1988-91. Independent prognostic factors were identified by Cox multivariate analysis. P-values < 0.05 were considered statistically significant.
RESULTS
CLINICAL RESULTS
The study series comprised 161 women (54 %) and 137 men (46 %). The median age at diagnosis was 53.9 (range 17-88.2) years. The majority of the patients were resident in the greater Helsinki area, and they represented all social groups. The social background was without prognostic significance. All patients were Caucasians. 42.3 % had had a naevus for several years at the spot where the melanoma later appeared. 9.7 % had had a naevus from early childhood or birth and 9.7 % had had no pre-existing naevus. Anamnesis provided no information concerning the presence of a naevus in 38.3 % of patients. One patient had had a burn injury in her index finger and a year later a melanoma developed on the burned spot. During follow-up, the lowest rate for developing melanoma metastases was for those who had had a pre-existing naevus for a short time, 15.9 %, as compared with 44.8 % for those who had not had a preexisting naevus and 37.9 % for those with a pre-existing naevus from birth or early childhood (p < 0.0001). In overall survival the prognosis was best for those who had had a pre-existing naevus for a short time, 11 % melanoma mortality, as compared with 24 % mortality for those who had not had a preexisting naevus at all and 31 % for those with a preexisting naevus from birth or early childhood (p = 0.004). The body-site of melanomas did not correlate to the different pre-existing naevus anamnesis. of all women's tumours were located in lower extremities compared to that of 18 % in men. When examined the prognostic value of different body-sites of tumours, the location on trunk was an adverse prognostic indicator in overall survival if tumour thickness was taken into account (p = 0.03). Tumour location in upper extremity proved to be a favorable prognostic sign in overall survival (p = 0.05) and tumour location in the sole an unfavorable one in disease-free and overall survival when the analyses were stratified by gender (p = 0.01, p = 0.04).
SURGICAL MANAGEMENT
The excision margins of the tumours varied, depending on the Breslow classification and location of the tumour. Excision margins diminished in the whole patient population during 1988-1991 from 5 cm median, range (0.5-7.0 cm) to 2 cm median, (p < 0.0001). They still, however, exceed the recommended resection dimensions, except in the Breslow ≥ 4 mm category (15, 21) . Primary closure was used in 43 %, transplantation of free skin in 40.6 %, skin flap in 12.1 %, muscle flap in 1.3 % and other reconstruction in 3 % as surgical techniques after excision of the tumour. The relatively wide resection margins explain the large proportion of skin grafts used.
The effect of the surgical margins on survival was evaluated taking into account gender and ulceration characteristics. No statistical significance was found in disease-free or overall survival between patients with a melanoma 0-0.74 mm thick irrespective of whether they were operated on with a margin ≤ 1 cm (n = 29) or > 1 cm (n = 64). A similar comparison of survival was made among patients with a melanoma 0.75-1.49 mm thick operated on with margins ≤ 1 cm (n = 6), 1.1-2 cm (n = 28) or > 2 cm (n = 36) and patients with a melanoma 1.5-3.99 mm thick operated on with margins of either ≤ 2 cm (n = 15) or > 2 cm (n = 66) and patients with a melanoma ≥ 4 mm thick operated on with a margin of ≤ 3 cm (n = 12) or wider (n = 20). We found no statistically significant differences in survival in any of those groups.
Regional lymph node dissections were performed in 128 patients; 78 % of them at primary operation and 22 % at a later phase. 74 % of the lymph node dissections were prophylactic and 26 % therapeutic in their indications. The most common type of lymph node dissection was of the axilla, 54.7 %, followed by the groin, 32.0 %, and neck, 11.7 %. The other 1.6 % consisted of supraclavicular and para-aortal node dissections. We compared separately Breslow groups < 1.5 mm and ≥ 1.5 mm in which the prophylactic lymph node had been dissected with those who had had primary excision only. Gender was taken into account. No significant differences were found in disease-free or overall survival in tumour thickness < 1.5 mm. In tumour thickness ≥ 1.5 mm, patients (n = 64) with a prophylactic lymph node dissection seemed to derive a marginal benefit in overall survival compared to those (n = 34) without it (p = 0.06).
PROGNOSIS
The median follow-up for overall survival was 9.5 years. At the end of the study, 17.8 % had died of melanoma and 15.4 % of some other cause; 199 patients were alive. 73 patients (24.5 %) developed metastases during the clinical follow-up period that was 4.8 years (median). The median time, counted from the moment of diagnosis to the time of the occurrence of the first metastasis, was 9.7 months. The most frequent site of metastasis was local lymph node (26.9 %), followed by subcutis (16.9 %), lung (16.3 %), skin (14.4 %), distant lymph nodes (10.6 %), brain (5.6 %), bone (5 %), and liver (4.3 %).
PROGNOSTIC FACTOR ANALYSIS
Tumour thickness, depth of tumour invasion and stage at diagnosis were all strong prognostic indicators in univariate analysis in both disease-free and overall survival (p < 0.0001). Figure 1 shows the cumulative survival curves for patients of different tumour thickness and figure 2 the cumulative survival curves for patients of different stages. Tumour ulceration seemed to be a strong adverse prognostic marker in disease-free and overall survival (p = 0.0005, p < 0.0002). The cumulative survival curves for patients of ulcerative and non-ulcerative tumours are shown in figure 3. The survival outcome was better for younger than older patients both in disease-free and overall survival (p = 0.04, p = 0.04). Women tended generally to survive better than men, but the difference was not statistically significant.
In Cox multivariate analysis for disease-free survival tumour thickness was the strongest prognostic factor (p = 0.01), followed by stage of tumour (p = 0.04). In Cox model for overall survival the strongest prognostic factor was stage of tumour (p = 0.01), followed by tumour thickness (p = 0.02) and tumour location on trunk (p = 0.03). Tumour location on trunk was an unfavorable prognosticator (Table 1 ).
DISCUSSION
We found that the prognosis for melanoma patients was improved; only 17.8 % died of melanoma and the 9.5-year overall survival rate was 66.8 %. Most of the tumours, (91 %), were stage I or II melanomas. Brandt described the first clinical study of Finnish melanoma population and its survival in 1956. 49.7 % of the patients (n = 112) had already regional or distant metastases at diagnosis, and the 5-year overall survival rate was only 20.5 % (17). Pakkanen demonstrated a study in 1977 with 691 melanoma patients. 75 % of men's and 80 % of women's tumours were in stage I at diagnosis, and the 10-year survival rate was 41 % for men and 53 % for women (18) . In the meta-analysis performed on 15 798 stage I and II melanoma patients by Balch et al. in 1992, the 5-year survival rate was 79 % (range 65-85 %), excluding all in situ melanomas (19) . Melanomas are diagnosed at an earlier phase; they are now thinner and less invasive (19) . We conclude that the prognosis for primary melanoma has markedly improved in Finland following the global tendency.
Tumour thickness measured in millimetres (Breslow classification) is the strongest and most important factor for determining the management and prognosis of the patient (5). The depth of invasion (Clark classification) is strongly correlated with the Breslow classification and has no additional prognos-tic value in general; in thin tissue such as the eyelid and ear it does, however, play an important prognostic role (20) . 5-22 % of thin melanomas (Breslow < 0.75 mm) metastasize, while some thick melanomas do not, indicating that there must be other factors contributing to the prognosis (21) . In our series 4.7 % of the most superficial melanomas, Breslow < 0.75 mm, developed metastasis. All of these tumours were classified as Clark level I-III groups. The AJCC has just recently revised the staging system for melanoma in order to reflect better independent prognostic factors (16) .
The number of women slightly exceeded that of men, and women tended to survive somewhat better than men (10-year disease-specific overall survival 85.3 % for women, 78.4 % for men, p = 0.24). Tumours in women were thinner (median tumour thickness 1.15 mm) than in men (median tumour 39 mm) , moreover, tumours were more often located in lower extremities in women and on trunk in men. Overall, melanomas occur almost equally in men and women (19) . Yet numerous studies have shown that female melanoma patients have a better survival rate than male patients (19) . Melanomas in women are more often located on the extremities, and are thinner and less frequently ulcerated. Even when these differences were minimized by grouping patients according to ulceration and site in a study of 6515 stage I and II melanoma patients by Balch et al. (19) , women with lesions of the extremities still had a better 10-year survival rate. According to the studies of Balch et al., Chang et al. and Garbe et al. in multivariate Cox models gender remains significant after adjustment for other prognostic factors including tumour thickness (19, 22, 23) . Whether the prognosis is inherently better for women is still unknown (19, 22, 23) .
We found that younger patients had better survival outcomes, in both disease-free and overall survival in univariate analysis. Similar conclusions were reached by Balch et al. (19) , who found that advancing age correlated significantly with a shortened time of survival in stage I-III tumours. Patient's age also correlated with melanoma thickness in stage I and II tumours, the older patients having the thicker tumours. Similarly we found that younger patients, < 53.9 years, had thinner tumours (median thickness 1.1 mm) than older patients, > 53.9 years, (whose median tumour thickness 1.9 mm). In contrast, in a study of 498 melanoma patients, Thörn et al. found that the prognosis was poor in the youngest age group in multivariate analysis (24) . Thus age seems to remain a controversial prognostic factor in the literature.
Tumour location on trunk was an independent adverse indicator in multivariate analysis for overall survival. It was also a significant adverse prognostic factor in univariate analysis stratified by tumour thickness. Tumour location in upper extremity was a beneficial prognostic marker in overall survival and tumour location in the sole an adverse one in diseasefree and overall survival in univariate analyses after stratified by gender. These findings accord with several other reports (22, 23) .
The different histories of the naevus anamnesis seemed to have prognostic influence on survival. Melanomas arising straight from the normal skin were more often ulcerated (20.7 %) and thicker (median Breslow classification 2.5 mm) than the other tumours and had a poorer prognosis than melanomas that had developed from a short-lived naevus. There were hardly any differences in median tumour thickness or ulceration characteristics between melanomas that had developed from a naevus present from birth or early childhood and one that had been there for a shorter time. However, melanomas that had developed from a naevus present from birth or early childhood had a poorer prognosis than those arising from a naevus present for a shorter time. This phenomenon raises the question whether there is some biologic difference in nevi present from birth or early childhood that make them act in a more aggressive manner.
In our study the melanomas had been removed in the late 1980s or early 1990s and, the surgical excision margins were markedly wider than recommended nowadays. It was at about that time, 1988, that the first prospective randomized study of this type was published by the World Health Organization Melanoma Group (8). A similar study was published in 1993 by the Intergroup Melanoma Surgical Program (7). On the basis of these prospective trials, it was recommended that the dimensions of surgical excision margins should be as follows: melanoma in situ 0.5 cm, melanoma < 1.0 mm thick 1 cm, melanoma 1.0-2.0 mm thick 1-2 cm, melanoma 2.0-4.0 mm thick 2 cm and melanoma > 4.0 mm thick 2-4 cm (7, 8, 12, 25) . In the course of our study, the dimensions of surgical margins were clearly reduced to conform with the above recommendation. In our patient population the width of the resection margin was not found to have any influence on survival. In our retrospectively analysed data we could not detect differences in survival in different width of surgical margins used in any Breslow category.
In addition to the classical prognostic factors it has become increasingly possible to define the various stages and substages of melanoma with considerable precision although some facets of melanoma behaviour are still unpredictable. One aspect of inter- est is vascularity of the tumour. In our recent study of primary melanomas, patients with high tumour vascularization had a slightly better prognosis than those with lower vascularity (26) . In the future, further studies will be needed to find out especially the influence of the patient's immunological and genetic factors in predicting the clinical course of melanoma (3, 27, 28, 29) .
